evidencegaps
Primary study · included by 2 reviews

Efficacy and Safety of [225Ac]Ac-PSMA-617 Augmented [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis.

Rosar 2021 (Pharmaceutics) · Rosar Florian, Krause Jonas, Bartholomä Mark, et al. · Pharmaceutics · 2021

Included by

Therapeutic outcomes of ²²⁵Ac/¹⁷⁷Lu-PSMA combination therapy in advanced metastatic Castration-Resistant prostate cancer: A systematic review and Meta-Analysis.
Non-Cochrane · intervention · 2026 · cited as Rosar 2021 (n=15) · Reference 31; Table 1; Figure 2A
Outcome this study informsPooled effectEvidenceCertainty
PSA decline of 50% or more (PSA50 response)
[225Ac]Ac-/[177Lu]Lu-PSMA combination (tandem) radioligand therapy vs None (single-arm studies)
Proportion (random-effects, REML) 0.47 [0.37, 0.56]8 studies · 323 participantsGRADE not reported
PSA decline of 50% or more (PSA50 response)
[225Ac]Ac-/[177Lu]Lu-PSMA combination (tandem) radioligand therapy vs None (single-arm studies)
Proportion (random-effects, REML) 0.44 [0.32, 0.56]6 studies · 169 participantsGRADE not reported
Beyond [177Lu]Lu-PSMA: a meta-analysis of safety and efficacy of emerging PSMA radioligand therapy agents.
Non-Cochrane · intervention · 2026 · cited as Rosar 2021b · Reference list refs 21-53; Table 2; Supplementary Table 5

The review does not say which of its outcomes this study informs.

2 including reviews in total.